Header Logo

Connection

BRIAN GILBERT to Humans

Back to Details
This is a "connection" page, showing publications BRIAN GILBERT has written about Humans.
BRIAN GILBERT
Connection Strength
0.245
Humans
  1. Consensus Recommendations for Clinical Pharmacist Integration into the Acute Stroke Care Team: Endorsed by the American College of Clinical Pharmacy, Neurocritical Care Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine, and affirmed by the American Academy of Neurology. J Am Coll Clin Pharm. 2026 Jul; 9(7):e70246.
    View in: PubMed
    Score: 0.026
  2. Identification and estimation of mediational effects of longitudinal modified treatment policies. Biostatistics. 2025 12 31; 26(1).
    View in: PubMed
    Score: 0.025
  3. Reversing Anticoagulants: Influence of Anticoagulation Stewardship and Key Considerations for Optimizing Outcomes. Ann Pharmacother. 2026 02; 60(2):196-201.
    View in: PubMed
    Score: 0.025
  4. Antiseizure medication practices in the adult traumatic brain injury patient population. Am J Emerg Med. 2024 12; 86:125-128.
    View in: PubMed
    Score: 0.023
  5. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013 Mar-Apr; 5(2):263-9.
    View in: PubMed
    Score: 0.010
  6. Augmented lung inflammation protects against influenza A pneumonia. PLoS One. 2009; 4(1):e4176.
    View in: PubMed
    Score: 0.008
  7. MegaRibavirin aerosol for the treatment of influenza A virus infections in mice. Antiviral Res. 2008 Jun; 78(3):223-9.
    View in: PubMed
    Score: 0.007
  8. Evaluation of Emergency Medicine Pharmacist Participation in Time to Oral Anticoagulation Reversal: A Systematic Review and Meta-Analysis. J Am Coll Clin Pharm. 2026 Feb; 9(2):e70156.
    View in: PubMed
    Score: 0.006
  9. Assessing the impact of emergency medicine pharmacists on fibrinolytic door-to-needle times in acute ischemic stroke: A systematic review and meta-analysis (Pharmacist-assisted Stroke Treatments I (PhAST-1)). Am J Emerg Med. 2025 12; 98:57-64.
    View in: PubMed
    Score: 0.006
  10. Impact of desmopressin on hematoma expansion in patients presenting to the emergency department on antiplatelet therapy. Am J Emerg Med. 2025 07; 93:126-131.
    View in: PubMed
    Score: 0.006
  11. EDucated: The emergency medicine pharmacotherapy literature of 2023. Am J Emerg Med. 2024 08; 82:166-173.
    View in: PubMed
    Score: 0.006
  12. In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections. Virology. 2023 09; 586:115-121.
    View in: PubMed
    Score: 0.005
  13. UpdatED: The emergency medicine pharmacotherapy literature of 2022. Am J Emerg Med. 2023 07; 69:136-142.
    View in: PubMed
    Score: 0.005
  14. Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation. Pharmacotherapy. 2023 03; 43(3):196-204.
    View in: PubMed
    Score: 0.005
  15. Adult Memory T Cell Responses to the Respiratory Syncytial Virus Fusion Protein During a Single RSV Season (2018-2019). Front Immunol. 2022; 13:823652.
    View in: PubMed
    Score: 0.005
  16. Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine. 2022 01 24; 40(3):536-543.
    View in: PubMed
    Score: 0.005
  17. Staying InformED: Top emergency Medicine pharmacotherapy articles of 2020. Am J Emerg Med. 2021 11; 49:200-205.
    View in: PubMed
    Score: 0.005
  18. A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. Vaccine. 2021 02 22; 39(8):1248-1256.
    View in: PubMed
    Score: 0.004
  19. Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis. Vaccine. 2021 02 12; 39(7):1044-1050.
    View in: PubMed
    Score: 0.004
  20. Electronic cigarettes disrupt lung lipid homeostasis and innate immunity independent of nicotine. J Clin Invest. 2019 10 01; 129(10):4290-4304.
    View in: PubMed
    Score: 0.004
  21. Major publications in critical care pharmacotherapy literature in 2018. J Crit Care. 2019 08; 52:200-207.
    View in: PubMed
    Score: 0.004
  22. Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway disease. J Biol Chem. 2018 06 29; 293(26):10026-10040.
    View in: PubMed
    Score: 0.004
  23. Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir. Eur J Pharmacol. 2018 Jan 05; 818:191-197.
    View in: PubMed
    Score: 0.004
  24. A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun. 2016 12 21; 7:13916.
    View in: PubMed
    Score: 0.003
  25. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
    View in: PubMed
    Score: 0.003
  26. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1264-73.
    View in: PubMed
    Score: 0.003
  27. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
    View in: PubMed
    Score: 0.003
  28. Benzimidazole analogs inhibit respiratory syncytial virus G protein function. Antiviral Res. 2015 Sep; 121:31-8.
    View in: PubMed
    Score: 0.003
  29. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26; 58(4):1630-43.
    View in: PubMed
    Score: 0.003
  30. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med. 2014 Nov; 6(11):1436-54.
    View in: PubMed
    Score: 0.003
  31. WFDC1 is a key modulator of inflammatory and wound repair responses. Am J Pathol. 2014 Nov; 184(11):2951-64.
    View in: PubMed
    Score: 0.003
  32. Essential role for autophagy in the maintenance of immunological memory against influenza infection. Nat Med. 2014 May; 20(5):503-10.
    View in: PubMed
    Score: 0.003
  33. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5992-7.
    View in: PubMed
    Score: 0.003
  34. Modeling dendritic cell vaccination for influenza prophylaxis: potential applications for niche populations. J Infect Dis. 2013 Jun 01; 207(11):1764-72.
    View in: PubMed
    Score: 0.003
  35. Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis. Cancer Prev Res (Phila). 2009 Apr; 2(4):361-9.
    View in: PubMed
    Score: 0.002
  36. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 2005 Oct; 68(1):18-26.
    View in: PubMed
    Score: 0.002
  37. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J Am Chem Soc. 2005 Sep 14; 127(36):12508-9.
    View in: PubMed
    Score: 0.002
  38. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res. 2004 Apr 01; 10(7):2319-26.
    View in: PubMed
    Score: 0.001
  39. Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther. 2003 May; 2(5):437-44.
    View in: PubMed
    Score: 0.001
  40. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res. 2002 Sep; 8(9):2970-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.